Molecular Formula | C18H22Cl2O5 |
Molar Mass | 389.27 |
Density | 1.332±0.06 g/cm3(Predicted) |
Melting Point | 87-89 °C |
Boling Point | 571.6±40.0 °C(Predicted) |
pKa | 4.33±0.10(Predicted) |
Storage Condition | 2-8℃ |
Use | SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY). |
In vitro study | SB204990 (SB) is a specific inhibitor of ACLY enzyme. SB204990 treatment leads to a decrease in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β-catenin levels. |
In vivo study | SB 204990, when administered orally to rats, is absorbed into the systemic circulation. When administered in the diet (0.05-0.25%, w/w) for 1 week, SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels. |